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Abstract 
 
Tuberous sclerosis complex (TSC) is a hamartomatous disease with defects in tuberin (TSC2) that can be autosomal 
dominant inheritance or spontaneous mutation. Mutation of the TSC-2 gene encoding tuberin on chromosome 16p13.3 
increases to the clinical disorder of tuberous sclerosis characterized by the development of hamartomas. In the present 
study, the antitumor activity of pcDNA3.1-TSC2 sense in an oral tongue cancer Supri’s clone-1 (SP-C1) was 
investigated. An expression vector containing sense-oriented rat TSC-2 pcDNA with pcDNA3.1 and transfected to cell 
(SP-C1) to regulate the expression of TSC-2 gene in each transfectant was constructed. MTT assay was performed to 
examine the SP-C1 cell growth suppression transfected by pcDNA3.1-TSC2. Caspase-3 and -9 were conducted to 
observe the induction of cell apoptosis. Western blotting analysis was carried out to determine the protein level of TSC-2, 
p27
Kip1
 and -tubulin. The results showed that, overexpression of TSC-2 exerted the growth inhibitory effect of SP-C1 
cell and markedly increased apoptosis via caspase-3 and -9 pathways (P=0.001). Sense-oriented SP-C1-cDNA3.1-TSC-2 
cancer cells have a high expression of p27
Kip1
. In conclusion, pcDNA3.1-TSC-2 sense increased the antitumor activity of 
oral tongue cancer SP-C1 cell through p27
Kip1
 induction. 
 
Key words: TSC-2, apoptosis, oral tongue cancer SP-C1, cell growth, p27
kip1 
 
Abstrak 
 
Tuberous sclerosis complex (TSC) merupakan suatu penyakit hamartoma dengan kelainan pada tuberin (TSC-2) akibat 
mutasi spontan atau warisan secara autosom dominan. Mutasi gen TSC-2 pada kromosom 16p13.3 meningkatkan 
kelainan tuberous sclerosis secara klinik dengan karakterisasi berkembangnya hamartoma. Pada penelitian ini dilakukan 
uji aktivitas antitumor pcDNA3.1-TSC-2 sense pada sel kanker lidah manusia Supri’s clone-1 (SP-C1). Konstruksi 
ekspresi vektor yang mengandung sense rat TSC-2 pcDNA dengan pcDNA3.1 ditransfeksikan ke sel SP-C1 untuk 
meregulasi ekspresi gen TSC-2 pada setiap transfeksi. Uji MTT dilakukan untuk menganalisis hambatan pertumbuhan sel 
SP-C1 yang ditransfeksi dengan pcDNA3.1-TSC-2.  Caspase-3 dan -9 digunakan untuk mengobservasi induksi apoptosis 
sel. Analisis Western blotting dipakai untuk menentukan tingkat protein TSC-2, p27
Kip1
 dan -tubulin. Hasil penelitian, 
peningkatan ekspresi TSC-2 menunjukkan efek hambatan pertumbuhan sel SP-C1 dan peningkatan apoptosis melalui 
jalur caspase-3 dan -9 (P=0,001). Sel kanker SP-C1-pc DNA 3.1-TSC-2 mempunyai ekspresi protein p27
Kip1
 yang tinggi. 
Kesimpulan, pc DNA 3.1-TSC-2 sense meningkatkan aktivitas antitumor sel kanker lidah SP-C1 melalui induksi p27
Kip1
. 
 
Kata kunci: TSC-2, apoptosis, kanker lidah, pertumbuhan sel, p27
Kip1
 
 
  
INTRODUCTION 
 
   Cancers of the oral cavity present a major health 
problem, as indicated by their high incidence in 
many parts of the world. In Southeast Asia 
countries, oral cancers are the most common form 
of cancer and constitute about a third of all cancers.
1
 
Oral cancers are characterized by a high degree of 
local invasion and a high rate of metastasis to the 
cervical lymph nodes. It frequently shows local 
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recurrence after initial treatment, probably due to 
micro invasion and/or micro metastasis of the tumor 
cells at the primary site.
2
 Treatment of oral cancer is 
conventionally a combination of surgery, radio-
therapy, and chemotherapy. However, the overall 
survival rates have not improved significantly in the 
last two decades.
3
 Also, the prognosis has not 
changed during the past 10 years.
 2
 This highlights 
the necessity for continued efforts to improve the 
treatment modalities using TSC2 gene. 
   Tuberous sclerotic complex (TSC) is known as an 
autosomal dominant tumor suppressor gene disorder 
affecting 1 in 6000 live births. TSC presents 
variably in multiple organs, including the brain, eye, 
skin, kidney, heart and oral.
4,5 
Linkage analysis of 
TSC resulted in the identification of two distinc 
genetic loci on chromosom 9 and 16.
6
 These genes 
are hamartin/TSC-1 (9q34) and tuberin/TSC-2 
(16q13).
7
 Germ-line TSC-1 and TSC-2 mutation 
appear to be inactivating and loss of heterozygosity 
at either the TSC-1 or TSC-2 region occurs in TSC 
tumors.
8-9
 Indicating that TSC-1 and TSC-2 are 
tumor suppressor gens. TSC-1 and TSC-2 follow 
the classic retinoblastoma tumor suppressor gene 
models and appear to function as negative growth 
regulators.
10
 TSC-1 and TSC-2 as tumor suppressor 
genes and when mutated, they give rise to abnormal 
cell proliferation and growth.
11
 The protein product 
of TSC-2 gene, tuberin, is expressed in variety of 
different cell  types.
12
  TSC-2 has a 190 kDa protein  
that contains a Rap1 GTPase-activating protein 
(GAP)-related domain and a coiled-coil domain 
believed to mediate its interaction with hamartin 
(TSC-1) and a carboxyl terminal GTPase.
13
 Re-
cently, TSC-2 may function as a tumor suppressor 
by induction of p27
Kip1
 protein.
5
 Interestingly, 
overexpression of TSC-2 results in reduced cell 
proliferation in vitro 14 and increased amounts of the 
cell cycle regulator p27
Kip1
 in rat fibroblast.
10
 
Therefore, TSC-2 is essential for p27
Kip1
 to regulate 
the cell cycle because tuberin can retain p27
Kip1
 
protein in nuclei of cancer cells.
10
 In addition, TSC-
2 may be closely associated with p27
Kip1
 to exert the 
function as tumor suppressor gene. 
   The purpose of the study was to investigate the 
antitumor activity of pcDNA3.1-TSC-2 sense in oral 
tongue cancer cell (SP-C1 cell) through induction of 
p27
Kip1
.  
 
MATERIALS AND METHODS 
 
   SP-C1 cells were isolated from a cervical lymph-
node metastasis of an oral squamous cell carcinoma 
patient in our laboratory.
15
 Cells were maintained in 
Dulbecco’s modified eagle medium (DMEM, Sig-
ma, St Louis, MO, USA) supplemented with 10% 
fetal calf serum (FCS, Moregate BioTech, Bulimba, 
Australia), 100 g/ml streptomycin, and 100 
units/ml penicillin. 
   The mammalian expression vectors pcDNA3.1-
TSC-2 containing sense-oriented rat TSC-2 cDNA 
was constructed as follows: pcDNA3.1 (+) (Invitro-
gen, Carlsbad, CA) is mammalian expression vec-
tors containing a CMV promoter. PcDNA3.1(+) 
was digested with Xba 1 (Takara Biomedicals, 
Kusatsu, Japan) and Xho 1 (Takara Biomedicals) 
and dephosphorylated by calf intestinal alkaline 
phosphatase (Roche Diagnostics, Mannheim, 
Germany). The rat TSC-2/pBluescript including the 
rat TSC-2 cDNA fragment (5.4 kbp Xba 1 and Xho 
1 fragment) was obtained as a generous gift from 
Dr. Koji Harada (Second Department of Oral 
Maxillofacial Surgery, Tokushima University, 
Japan). This fragment was ligated to the prepared 
cloning site of pcDNA3.1 (+) by T4 DNA ligase 
(Takara Biomedicals). The direction of the ligated 
fragment was confirmed by sequencing analysis. 
Furthermore, cells (5x10
5
 cells/dish) were seeded in 
100 mm culture dishes (Falcon, USA) in DMEM 
supplemented with 10% FCS. Twenty-four hours 
later, the cells were transfected with 5 g of 
pcDNA3.1-TSC-2 or pcDNA3.1 without inserted 
(empty vector or neo) by using the Superfect reagent  
(Qiagen, Hilden, Germany). The cells were in-
cubated for 48 hours in DMEM containing 10% 
FCS. Then, trypsinized and seeded at 1:5 ratio in 
100 mm culture dishes in DMEM containing 10% 
FCS. Forty-eight hours later, the cells were switched 
to a selective medium containing Geneticin (800 
mg/ml G418). After 14 days of culture in the 
selective medium, ten representative G418-resistant 
clones were isolated and expanded in a 24-well 
cluster dish (Falcon). 
   SP-C1-transfected cells were seeded on 96-well 
plates (Falcon, NJ, USA) at 2 x 10
4 
cells per well in 
DMEM containing 10% FCS. Cells were incubated 
for 24 and 48 hours. After incubation, the number of 
cells was quantitated by BioRad microplate reader 
machine (Sigma-Aldrich, USA) with 540 nm wave-
length. MTT solution contains 3-(4,5-dimethyl-
thiazol- 2-yl)-2,5-diphenytetrazolium bromide (Sig-
ma-Aldrich) was used in examination. 
17 
   Cell lysates were prepared from SP-C1 transfected 
cells from a Falcon tissue culture. Briefly, samples 
containing equal amounts of protein (50 g) were 
electrophoresed on a SDS-polyacrylamide gel and 
transferred to a nitrocellulose filter (PVDF mem-
brane: Bio Rad, Hercules, CA, USA). The filters 
were blocked in TBS containing 5% nonfat milk 
powder at 37
0
C for 1 hour and then incubated with a 
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1: 500 dilution of the monoclonal antibody against 
Tuberin (TSC-2) protein (N-19, rabbit polyclonal 
antibody, Santa Cruz Biotechnology, CA, USA), 
and p27 protein (clone 1B4, monoclonal antibody, 
Novocastra Laboratories, New Castle, UK), as the 
primary antibody and an Amersham ECL kit 
(Amersham Pharmacia Biotech). Anti--tubulin 
monoclonal antibody (Zymed laboratories, San 
Fransisco, CA, USA) was used for normalization of 
Western blot analysis. 
   Induction of apoptosis was measured using the 
colorimetric assay kit (caspase-3 and caspase-9; 
BioVision Research Product, CA, USA) according 
to the manufacturer’s directions. Briefly, equal 
amounts of tissue extracts prepared from SP-C1 
transfected with pcDNA3.1-TSC2 or pcDNA3.1-
neo were incubated with the substrate (DVED-pNA 
or LEHD-pNA) in the assay buffer for 2 hours at 
37
0
C. Absorbance was measured at 405 nm using a 
microplate reader (BioRad, USA). Each determina-
tion was performed in triplicate. 
   Statistical analysis was performed with a Stat 
Works Program for Macintosh computers (Cricket 
Software, Philadelphia, PA, USA). Data was ana-
lyzed by Post Hoc test (Student’s t-test) with signi-
ficant level 95%. 
 
RESULTS 
 
   Relative cell number was evaluated by comparing 
the absorbent of each cell using MTT assay on 24 
and 48 hours. Cell number of SP-C1-pcDNA3.1-
TSC-2 was significantly decreased compared with 
that of SP-C1-pcDNA3.1-neo (untreated control) on 
24 and 48 hours (p =0,001) (Figure 1). 
0
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24 hours 48 hours
neo
TSC-2
**
 
Figure 1.  Relative cell number of SP-C1-pcDNA3.1-
TSC-2 and SP-C1-pcDNA3.1- neo at 24 and 48 
hours by MTT assay (**, p < 0.001) 
 
   Western blotting analysis revealed the up-
regulation of TSC2 and p27
Kip1
 were detected in 
sense-TSC-2 transfectans when compared with that 
in control cells which were transfected with 
pcDNA3.1-neo. The expression of -tubulin as an 
internal control was approximately the same in all of 
the tumors (Figure 2). 
 
p27Kip1
-tubulin
SP-C1-pcDNA3.1-
neo TSC-2
TSC-2
 
 
Figure 2. Expressions of TSC-2, p27
Kip1
 and -tubulin in 
SP-C1-pcDNA3.1-TSC-2 and SP-C1-pcDNA 
3.1- neo by Western blotting analyzed 
 
   The activity of caspase-3 and -9 in sense-TSC-2 
transfectans or control cells was examined using 
colorimetric assay. As seen in Figure 3, TSC-2 
transfectans was markedly increased the proteolytic 
activities of caspase-3 (2.4 fold) and -9 (1.8 fold) as 
compared with that of control cells (p=0.000) 
(Figure 3). 
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Figure 3. Activation of caspase-3 and -9 in SP-C1-
pcDNA3.1-TSC-2 and SP-C1- pcDNA 3.1- neo 
at 48 hours incubated (**, p < 0.001 and *, p < 
0.05) 
SP-C1-pcDNA3.1- 
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DISCUSSION 
 
   Treatment strategy using gene transfection tech-
nique on human head and neck cancer included oral 
tongue cancer has a main attention of clinicians or 
oncologists in the world and in the last decade. TSC-
2 is used as a tumor suppressor gene and widely 
used in suppression of TSC-2 syndrome (hamar-
toma). The autosomal dominant disease tuberous 
sclerosis complex (TSC) is caused by mutation in 
either TSC-1 on chromosome 9q34 encoding 
hamartin, or TSC-2 on chromosome 16p13.3 en-
coding tuberin. Mutations of either the TSC-1 or the 
TSC-2 gene result in the syndrome of tuberous 
sclerosis that affects multiple organs with the 
development of hamartomas including cortical tuber 
of the brain, angiofibroma of the skin, rhabdo-
myoma of the heart and angiomyeolipoma of the 
kidney.
19
 TSC-2 seemed to play an important role in 
exerting the function of p27
Kip1
 protein as a cell 
cycle regulator by retaining p27
Kip1
 protein in nuclei 
of cancer cells.
10
 However, the true biochemical 
functions of TSC-2 as a tumor suppressor and the 
underlying mechanisms responsible for pathogene-
sis of TSC-related hamartomas have not been 
clarified yet. 
   In the present study overexpression of TSC-2 
exerted the antitumor effect on human oral tongue 
cancer cells whether they have high expression of 
p27
Kip1
 protein. These finding may suggest that 
TSC-2 can regulate the p27
Kip1
 protein at up-stream 
of p27
Kip1
. It means that TSC-2 may be more 
important as a prognostic factor in oral SCC rather 
than p27
Kip1
. Next results revealed that a significant 
suppression of tumor growth of sense transfectant 
(SP-C1-TSC-2 cells) in vitro. These findings may 
suggest that up-regulation of TSC-2 in tumor cells 
will be safe for the body and TSC-2 can be used as 
molecular target for gene therapy if the precise 
function of TSC-2 can be clarified. Furthermore, 
apoptosis induction was detected in SP-C1-
pcDNA3.1-TSC2 sense through high level of 
caspase-3 and-9 compared with that of SP-C1-
pcDNA3.1-neo. It is suggested that apoptosis 
induction of SP-C1 cancer cell can arise via 
extrinsic and intrinsic pathways. Azuma et al. 20 
reported that high level of proteolytic activity 
caspase-3 showed a high cleavage of protein in 
receptor-induced apoptosis (extrinsic pathway), and 
induction of caspase-9 level revealed a high 
proteolytic activity in chemical-induced apoptosis 
(intrinsic pathway).  
    In conclusion, TSC-2 may exert the antitumor 
effect on human oral tongue cancer (SP-C1) cell 
through p27 
Kip1 
protein induction. 
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